Sun J X, Cipriano A, Chan K, John V A
Department, Pharmaceuticals Division, Ciba-Geigy Corporation, Ardsley, New York 10502.
Eur J Clin Pharmacol. 1994;47(3):285-9. doi: 10.1007/BF02570510.
Pharmacokinetic interaction between benazepril (ACE inhibitor) and amlodipine (calcium channel blocker) was studied in 12 healthy subjects. Single doses of benazepril hydrochloride (10-mg tablet) and amlodipine besylate (tablet equivalent to 5 mg amlodipine) were administered alone or in combination according to a three-way, Latin-Square, randomized cross-over design. Serial blood samples were collected following each administration for the determination of benazepril and its active metabolite benazeprilat and amlodipine. The mean values of AUC (0-4 h), Cmax and Tmax for benazepril given as combination versus given alone were 161 vs 140 ng.h.ml-1, 168 vs 149 ng.ml-1, and 0.5 vs 0.6 h. The mean values of AUC (0-24 h), Cmax and Tmax for benazeprilat after benazepril given as combination versus given alone were 1470 vs 1410 ng.h.ml-1, 292 vs 257 ng.ml-1, and 1.7 vs 1.5 h. The mean values of AUC (0-144 h), Cmax and Tmax for amlodipine given as combination versus given alone were 118 vs 114 ng.h.ml-1, 2.5 vs 2.3 ng.ml-1, and 8.3 vs 9.0 h. The differences in these pharmacokinetic parameters between the combination and monotherapy treatments were not statistically significant based on ANOVA. The results of this study indicate that no pharmacokinetic interaction existed between the two drugs.
在12名健康受试者中研究了贝那普利(一种血管紧张素转换酶抑制剂)和氨氯地平(一种钙通道阻滞剂)之间的药代动力学相互作用。按照三因素拉丁方随机交叉设计,单独或联合给予单剂量的盐酸贝那普利(10毫克片剂)和苯磺酸氨氯地平(相当于5毫克氨氯地平的片剂)。每次给药后采集系列血样,以测定贝那普利及其活性代谢产物贝那普利拉和氨氯地平。联合给药与单独给药相比,贝那普利的AUC(0 - 4小时)、Cmax和Tmax的平均值分别为161对140纳克·小时·毫升⁻¹、168对149纳克·毫升⁻¹、0.5对0.6小时。贝那普利联合给药与单独给药后,贝那普利拉的AUC(0 - 24小时)、Cmax和Tmax的平均值分别为1470对1410纳克·小时·毫升⁻¹、292对257纳克·毫升⁻¹、1.7对1.5小时。联合给药与单药治疗相比,氨氯地平的AUC(0 - 144小时)、Cmax和Tmax的平均值分别为118对114纳克·小时·毫升⁻¹、2.5对2.3纳克·毫升⁻¹、8.3对9.0小时。基于方差分析,联合治疗与单药治疗之间这些药代动力学参数的差异无统计学意义。本研究结果表明,这两种药物之间不存在药代动力学相互作用。